Comparative Pharmacology
Head-to-head clinical analysis: ASACOL versus ASACOL HD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASACOL versus ASACOL HD.
ASACOL vs ASACOL HD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Asacol (mesalamine) is an aminosalicylate that exerts anti-inflammatory effects in the colon via inhibition of prostaglandin and leukotriene synthesis, particularly by blocking cyclooxygenase and lipoxygenase pathways, and by scavenging reactive oxygen species. It also inhibits cytokine production and reduces mucosal inflammation.
Mesalamine, the active ingredient, is a 5-aminosalicylic acid (5-ASA) derivative that acts locally in the colon to reduce inflammation by inhibiting prostaglandin production and leukotriene synthesis, likely through scavenging free radicals and blocking cytokine release.
800 mg orally three times daily or 1600 mg three times daily for 6 weeks; maintenance: 1.6 g daily in divided doses.
2 tablets (1600 mg) once daily with or without food.
None Documented
None Documented
Terminal half-life: 0.6-1.4 hours for 5-ASA; 6-12 hours for N-acetyl-5-ASA. Clinical context: short t1/2 necessitates multiple daily dosing for sustained colonic exposure.
Terminal elimination half-life is 5-10 hours for 5-ASA and 5-10 hours for acetyl-5-ASA; clinically, it supports twice-daily dosing.
Renal (80% as 5-ASA and N-acetyl-5-ASA), fecal (20%)
Primarily renal excretion of acetyl-5-ASA (about 80% of absorbed dose) and unchanged 5-ASA; minor fecal elimination (<20%).
Category C
Category C
Aminosalicylate
Aminosalicylate